Showing results (1291-1300 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 19, 2017
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumorsJanice M Mehnert, Gerald Edelman, Mark Stein, et al.
Investigational New Drugs|June 3, 2008
Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapyDavid E Durrant, Joanna Richards, Ashutosh Tripathi, et al.
Investigational New Drugs|June 17, 2008
Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancerManon Buijs, Josephina A Vossen, Jean-Francois H Geschwind, et al.
Investigational New Drugs|June 14, 2008
Suppressive effects of novel derivatives prepared from Aconitum alkaloids on tumor growthMasaharu Hazawa, Koji Wada, Kenji Takahashi, et al.
Investigational New Drugs|June 6, 2008
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumorsMichael J Overman, Gauri Varadhachary, Scott Kopetz, et al.
Investigational New Drugs|March 24, 2019
Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumorTetsuhide Ito, Takuji Okusaka, Toshirou Nishida, et al.
Investigational New Drugs|July 18, 2019
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonistsLaura Muñoz-Moreno, María J Carmena, Andrew V Schally, et al.
Investigational New Drugs|July 14, 2019
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 studySu Young Jung, Sunjin Hwang, Jeffery M Clarke, et al.
Investigational New Drugs|September 24, 2022
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumabNobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, et al.
Investigational New Drugs|July 20, 2012
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft modelsCéline Clémenson, Erwan Jouannot, Ana Merino-Trigo, et al.
Pageof 372